OSE Immunotherapeutics Balance Sheet Health
Financial Health criteria checks 5/6
OSE Immunotherapeutics has a total shareholder equity of €81.4M and total debt of €40.4M, which brings its debt-to-equity ratio to 49.6%. Its total assets and total liabilities are €140.9M and €59.5M respectively. OSE Immunotherapeutics's EBIT is €53.8M making its interest coverage ratio 23.2. It has cash and short-term investments of €75.7M.
Key information
49.6%
Debt to equity ratio
€40.39m
Debt
| Interest coverage ratio | 23.2x |
| Cash | €75.75m |
| Equity | €81.45m |
| Total liabilities | €59.47m |
| Total assets | €140.92m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0RAD's short term assets (€85.8M) exceed its short term liabilities (€17.4M).
Long Term Liabilities: 0RAD's short term assets (€85.8M) exceed its long term liabilities (€42.1M).
Debt to Equity History and Analysis
Debt Level: 0RAD has more cash than its total debt.
Reducing Debt: 0RAD's debt to equity ratio has increased from 8.2% to 49.6% over the past 5 years.
Debt Coverage: 0RAD's debt is well covered by operating cash flow (144.5%).
Interest Coverage: 0RAD's interest payments on its debt are well covered by EBIT (23.2x coverage).